Results 71 to 80 of about 2,109,479 (260)
Shear viscosity of a superfluid Fermi gas in the unitarity limit
, 2007 We compute the shear viscosity of a superfluid atomic Fermi gas in the unitarity limit. The unitarity limit is characterized by a divergent scattering length between the atoms, and it has been argued that this will result in a very small viscosity.
C. Manuel +7 more
core +1 more source
Pseudo-factor-XI deficiency: effect of an inhibitor of factor XI adsorption to surface [PDF]
Blood, 1981 Abstract Recently we have described a normal plasma activity that modulates contact activation by inhibiting adsorption of factor XI to activating surfaces. Here we report the first identified case in which a patient has abnormal clotting tests due to an excess of a similar activity.
S, Schiffman +3 more
openaire +2 more sources
Aging and Cancer, EarlyView.This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel +4 more
wiley +1 more source
Modified DMRG algorithm for the zigzag spin-1/2 chain with frustrated antiferromagnetic exchange: Comparison with field theory at large $J_2/J_1$ [PDF]
, 2010 A modified density matrix renormalization group (DMRG) algorithm is applied to the zigzag spin-1/2 chain with frustrated antiferromagnetic exchange $J_1$, $J_2$ between first and second neighbors. The modified algorithm yields accurate results up to $J_2/
Diptiman Sen +4 more
core +2 more sources
Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Spinocerebellar ataxia type 3 (SCA3) is a genetically defined ataxia. The Scale for Assessment and Rating of Ataxia (SARA) is a clinician‐reported outcome that measures ataxia severity at a single time point. In its standard application, SARA fails to capture short‐term fluctuations, limiting its sensitivity in trials.
Marcus Grobe‐Einsler +20 more
wiley +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
Factor XI Kinetics after Plasma Exchange in Severe Factor XI Deficiency [PDF]
Pathophysiology of Haemostasis and Thrombosis, 1986 Plasma exchange in a patient with factor XI deficiency allowed the determination of the factor XI disappearance time. The decay curve showed a biphasic pattern with a t<sub>½</sub> of 12.3 h during the first 3 days, followed by a slower decay with a t<sub>½</sub> of 121 h.
I R, Nováková +3 more
openaire +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers +7 more
wiley +1 more source
A Monte Carlo Study of Correlations in Quantum Spin Ladders
, 1996 We study antiferromagnetic spin--1/2 Heisenberg ladders, comprised of $n_c$ chains ($2 \leq n_c \leq 6$) with ratio $J_{\bot}/J_{\|}$ of inter-- to intra--chain couplings.
D.C. Johnston +28 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source